Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Scheduled to Reverse Split on Monday, April 6th

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) shares are going to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 3rd.

Biodexa Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ BDRX opened at $0.61 on Thursday. The firm’s 50-day moving average is $1.15 and its two-hundred day moving average is $3.79. Biodexa Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $19.30.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last issued its quarterly earnings data on Friday, March 27th. The company reported $0.70 earnings per share for the quarter. As a group, equities analysts predict that Biodexa Pharmaceuticals will post -1.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on BDRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biodexa Pharmaceuticals presently has an average rating of “Sell”.

Hedge Funds Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors and hedge funds.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.